Brought to you by 
BMS, Tibotec combine HCV candidates for all oral direct-acting antiretroviral regimen
19 Apr 2012
Executive Summary
Bristol-Myers Squibb Co. and Johnson & Johnson’s Tibotec Pharmaceuticals Ltd. (the infectious disease division of Janssen Pharmaceutical Co.’s Janssen Pharmaceuticals Inc.) have agreed to create an all-oral regimen for chronic hepatitis C by combining their Phase III direct-acting antiretrovirals: BMS’s daclatasvir (BMS790052) with Tibotec’s TMC435.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, Tibotec combine HCV candidates for all oral direct-acting antiretroviral regimen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice